Device Trial Radar · NCT06528600
Comparative Study of Two Hyaluronic Acid Formulation in the Management of Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Jul 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Sep 16, 2020
Primary completion
Mar 15, 2024
Study completion Jun 15, 2024
Sponsor
- Lead sponsor
- Fidia Farmaceutici s.p.a.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this randomized, double-blind, active-controlled, non-inferiority study is to compare the effectiveness and safety of a single injection of Hymovis ONE®, a sodium hyaluronate formulation, to Monovisc™, another sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens. This study consists of a 2-week period for screening, one baseline treatment visit, and a 26- week evaluation phase. Subjects will be randomized to receive a single intra-articular (IA) injection of either Hymovis ONE® or Monovisc™ into the knee using an 18-20 gauge needle.
Conditions
- Osteoarthritis, Knee
Interventions
Hymovis ONEDevice
Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
MonoviscDevice
Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain relief compared to baselineTime frame: week 12
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
A.O. Ospedale Cardarelli I Ortopedia
Naples, Italy
AOU Federico II Napoli UOC Ortopedia e Traumatologia
Naples, Italy
P.O. Ospedale del Mare ASL 1 Napoli U.O.C. Ortopedia
Naples, Italy
16 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.